Mariko Sasaki-Noguchi
Yokohama, 2448602, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Trans-omics landscape of systemic vasculitis identified matrix metalloproteinase 12 as a novel signature molecule.
Journal: Rheumatology (Oxford, England)
Published: January 06, 2025
IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model.
Journal: Frontiers in neurology
Published: December 15, 2023
Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis.
Journal: Rheumatology (Oxford, England)
Published: October 11, 2023
Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan.
Journal: TH open : companion journal to thrombosis and haemostasis
Published: August 30, 2023
Longitudinal monitoring of circulating immune cell phenotypes in anti-neutrophil cytoplasmic antibody-associated vasculitis.
Journal: Autoimmunity reviews
Published: December 10, 2022
Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis.
Journal: Arthritis research & therapy
Published: September 11, 2022
Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: May 17, 2022
Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.
Journal: Pediatric blood & cancer
Published: November 25, 2021
Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A.
Journal: Thrombosis and haemostasis
Published: February 28, 2021
Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
Journal: International journal of hematology
Published: December 01, 2020
Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.
Journal: Thrombosis and haemostasis
Published: May 09, 2020
Last Updated: 09/26/2026